Pfizer RSV vaccine that protects infants could receive FDA approval this summer
Publishing timestamp: 2023-02-22 11:23:30
Summary
The FDA is reviewing Pfizer's RSV vaccine on an expedited basis and is expected to make a decision on whether to clear the shot in August. The single-dose vaccine is administered to expectant mothers in late second to third trimester of their pregnancy and is 82% effective at preventing severe disease from RSV in newborns during first 90 days of life. RSV exploded last fall as public largely stopped wearing masks and ended social distancing as Covid-19 pandemic eased.
Sentiment: NEUTRAL
Tickers: PFE,
Keywords: health care industry, business news, business, politics, biotechnology, coronavirus, epidemics, pfizer inc, biotech and pharmaceuticals, disease outbreaks, breaking news: business, pandemics, u.s. economy,